Publications by authors named "M Khoshkhui"
Chronic urticaria is a persistent skin condition characterized by recurrent wheals (hives) and/or angioedema lasting more than six weeks, significantly impacting quality of life and often requiring long-term management. Limited access to costly treatments like omalizumab poses challenges in low-income countries with high healthcare expenses and limited insurance coverage, prompting research into cost-effective dosages for effective management. This study aims to find the most cost-effective dosage for treating chronic urticaria in countries with healthcare affordability challenges.
View Article and Find Full Text PDFArticle Synopsis
- CRUSE® is an app designed for people with chronic spontaneous urticaria (CSU) to track their symptoms using visual analogue scales (VASs), aiming to assess the app's effectiveness in measuring disease activity.
- A study analyzed three VASs related to CSU impact on daily life, including one specifically for the severity of urticaria, one for productivity, and a general health measure (EQ-5D), using data from nearly 6,000 patients over many days.
- The results showed that the CRUSE® app's VASs demonstrate strong validity and reliability, with the "VAS urticaria" being most effective in capturing symptom changes, while the minimal important difference (MID) values indicated meaningful changes
Background: Chronic spontaneous urticaria (CSU) is a common inflammatory disorder characterized by wheals, angioedema, or both, for more than 6 weeks. Autoimmunity is held to be one of the most frequent causes, but little is known about the expression and relevance of autoimmunity-driving genes in CSU, such as STAT3, STAT1, IL-27p28, and IL-12p35.
Objective: To investigate CSU patients or the expression of STAT3, STAT1, IL-27p28, and IL-12p35 and possible links to clinical features.
Noninfectious Complications in B-Lymphopenic Common Variable Immunodeficiency.
J Investig Allergol Clin Immunol
July 2024
Article Synopsis
- Common variable immunodeficiency (CVID) is a significant disorder characterized by both infectious and noninfectious complications, with 66.4% of patients experiencing noninfectious issues such as enteropathy and autoimmunity.
- In a study of 387 CVID patients, those with B-cell lymphopenia showed higher rates of certain complications, particularly in the dermatologic, endocrine, and musculoskeletal systems.
- The study highlights the need for routine monitoring and appropriate treatment strategies, including medication alongside immunoglobulin therapy, to manage complications associated with CVID effectively.
Allergen-specific immunotherapy is the only disease-modifying treatment for IgE-mediated allergic disorders. Intra lymphatic immunotherapy (ILIT) is an efficacious and time-saving alternative to subcutaneous immunotherapy (SCIT). This study aimed to evaluate the effects and safety of ILIT in patients with moderate to severe allergic rhinitis.
View Article and Find Full Text PDF